Pharmaceuticals turnover in the quarter was £4,158 million, up
4% AER, 2% CER. HIV sales were up 7% AER, 4% CER, to
£1,121 million, driven by growth of
Tivicay
and
Juluca.
Respiratory sales were up 29% AER, 25% CER,
to £631 million, on growth of
Trelegy
and
Nucala
. Sales of Established Pharmaceuticals
declined 5% AER, 6% CER to £2,242 million, including the
impact of the loss of exclusivity of
Advair
, partly offset by the launches of authorised
generics for
Advair
and
Ventolin
in the US.
In the US, sales grew 8% AER, 1% CER, reflecting growth in HIV,
Respiratory and
Benlysta
, more than offsetting the decline in Established
Products including the loss of exclusivity
of
Advair
. In Europe, sales declined 2% AER, 1% CER,
with strong growth in Respiratory offset by declines in Established
Pharmaceuticals. International grew 4% AER and 4%
CER, with growth in HIV and Respiratory.
Respiratory
New Respiratory sales (
Ellipta
products plus
Nucala
) were up 29% AER, 25% CER, with strong growth in
all regions. Higher demand for
Trelegy
Ellipta
and
Nucala
resulted in US growth of 27% AER, 19% CER
and Europe growth of 31% AER, 33% CER. International grew 31%
AER, 30% CER, including
Relvar/Breo
Ellipta
up
19%.
Sales of
Nucala
were £152 million in the quarter and
grew 46% AER, 41% CER, continuing to benefit from the global
rollout of the product. US sales of
Nucala
grew 44% AER, 36% CER to £85
million.
Sales of
Ellipta
products were up 24% AER, 20% CER to
£479 million driven by continued growth in all regions.
In the US, sales grew 22% AER, 14% CER, reflecting further market
share gains partly offset by the impact of continued competitive
pricing pressures, particularly for ICS/LABA products. In
Europe, sales grew 27% AER, 28% CER. In the US, sales
of
Trelegy
Ellipta
contributed
£66 million in the quarter, continuing to benefit from the
expanded US label.
Relvar/Breo Ellipta
sales
were down 2% AER, 5% CER. In the US,
Relvar/Breo
Ellipta
declined 22% AER,
27% CER, impacted by competitive pricing pressures and the impact
of generic
Advair
on the ICS/LABA market. In Europe and
International,
Relvar/Breo
Ellipta
continued to grow,
up 8% AER, 10% CER and 23% AER, 19% CER
respectively.
HIV
HIV sales increased 7% AER, 4% CER to £1,121 million in the
quarter. The growth was driven by the dolutegravir franchise,
which grew 11% AER, 7% CER in the quarter, partly offset by a
decline in the rest of the portfolio. Sales of dolutegravir
products were £1,067 million in the quarter,
with
Triumeq
and
Tivicay
delivering sales of £614 million and
£383 million, respectively.
Juluca
, the first of our two drug regimens, recorded
sales of £70 million driven by continued share
growth.
The US and International regions grew 10% AER, 3% CER and 28% AER,
29% CER respectively, driven by
Juluca
in the US and a
Tivicay
tender in International. In Europe,
dolutegravir products declined 3% AER, 2% CER with volume growth
offset by price erosion and government clawback adjustments in Q1
2018.
The remaining portfolio delivered sales of £54 million,
representing 5% of total HIV sales, declining 36% AER, 35%
CER. This reflected continued competition from generic
products and transition to new regimens and reduced the overall
growth of total HIV by approximately three percentage
points.
Immuno-inflammation
Sales of
Benlysta
in the quarter were up 21% AER, 15% CER to
£121 million, including sales of the sub-cutaneous formulation
of £47 million. In the US,
Benlysta
grew 18% AER, 11% CER to £105
million.
Oncology
Zejula
recorded sales of
£42 million, following the completion of the acquisition of
Tesaro on 22 January 2019.
Established
Pharmaceuticals
Sales of Established Pharmaceuticals in the quarter were
£2,242 million, down 5% AER, 6% CER.
Established Respiratory products were flat at AER but declined 2%
CER to £1,083 million, with the decline
in
Advair/Seretide
partially
offset by higher sales of
Ventolin
and allergy products
.
In the US, a generic version
of
Advair
was launched in February, resulting in 23%
AER, 27% CER decline in the quarter. In
Europe,
Seretide
sales were down 20% AER, 19% CER to £133
million, reflecting continued competition from generic
products and the transition of the Respiratory portfolio to newer
products. In International, sales of
Seretide
were up 4% AER and
CER.
Ventolin
grew by 36% AER, 33% CER driven by strong
initial sales from the launch of an authorised generic version in
the US.
The remainder of the Established Pharmaceuticals portfolio declined
by 10% AER, 9% CER, including
Lamictal
which declined 10% AER, 12% CER to £132
million due to generic competition in the US, together with
declines in
Relenza
,
Coreg
and
Levitra
.
|